(Q43685787)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Michael J. Sweeting

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Brian J Thomson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

William L. Irving

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Marina Grishchenko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Daniela De Angelis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Stephen D Ryder

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Trent HCV Study Group

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

31 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Technology Assessment in Health Care

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

171-180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

The burden of hepatitis C in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

A comparison of fibrosis progression in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

An empirical comparison of EQ-5D and SF-6D in liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Statistical approaches to handling uncertainty in health economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Natural histories of hepatitis C virus infection in men and women simulated by the Markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

Viral hepatitis and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

inferred from DOI database lookup

7 January 2021

based on heuristic

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

inferred from DOI database lookup

7 January 2021

based on heuristic

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090229

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S0266462309090229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19331708%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference